Effect of lookback period length on disease incidence estimates in claims databases - 10/09/25
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Highlights/ What is new? |
• | Key findings |
• | In this epidemiological study conducted on the national French claims database, according to the diseases, incidence estimates are overestimated to varying extents when the lookback period is shorter than 5 years. |
• | What this adds to what was known? |
• | Based on a reference lookback period of 4.75 years, to limit the overestimation of diseases’ incidence to 5%, the length of the lookback period should be 1.75, 2.5, and 3.25 years for HIV/AIDS, chronic liver disease, and heart failure, respectively. |
• | What is the implication and what should change now? |
• | If the length of the lookback period varies by inclusion year in a study, this can affect the annual diseases’ incidence estimates over time. |
• | Simulations should be carried out at the start of epidemiological studies conducted on claims databases to choose the optimal lookback period length. |
Abstract |
Purpose |
Claims databases are used to examine diseases’ and comorbidities’ occurrences. However, the date of diagnosis is not available in those databases. Among the population of French adults at-risk of pneumococcal or influenza infections (i.e. patients with immunocompromised status or chronic medical conditions), three chronic diseases were selected for this study. The aim of the study was to determine the effect of the length of the lookback period on the incidence estimates of heart failure (HF), chronic liver disease, and HIV/AIDS using a claims database.
Methods |
This retrospective longitudinal observational study was performed using secondary pseudonymized data from the French National Health Data System (SNDS). Prevalent patients with the three diseases in 2020 were identified using algorithms published by the National Health Insurance. The incident patients were those without any disease-identifying criterion during the lookback period of interest —which varied for the purpose of the study from 3 to 57 months. The overestimation of the incident population was computed for each lookback period length.
Results |
With a 1-year lookback period, the incidences of patients with HF, chronic liver disease, and HIV/AIDS were overestimated by 20.3%, 19.2%, and 12.0%, respectively. The 5% overestimation threshold was reached with a lookback period of 3.75 years, 2.5 years and 1.75 years, for HF, chronic liver disease, and HIV/AIDS, respectively.
Conclusion |
The choice of the length of the lookback period for estimating incidence is an important methodological point. Depending on the disease and the length of the lookback period, the overestimation of incidence estimates varies.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Key words (6 words max, American spelling, index-appropriate terms) : Claims data, estimation, epidemiology, real-world evidence, bias, health services research
Plan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?